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ABSTRACT
Aims/Introduction: To examine the association between liver histological features and
organ-specific insulin resistance indices calculated from 75-g oral glucose tolerance test
data in patients with non-alcoholic fatty liver disease.
Materials and Methods: Liver biopsy specimens were obtained from 72 patients with
non-alcoholic fatty liver disease, and were scored for steatosis, grade and stage. Hepatic
and skeletal muscle insulin resistance indices (hepatic insulin resistance index and Matsuda
index, respectively) were calculated from 75-g oral glucose tolerance test data, and meta-
bolic clearance rate was measured using the euglycemic hyperinsulinemic clamp method.
Results: The degree of hepatic steatosis, and grade and stage of non-alcoholic steato-
hepatitis were significantly correlated with Matsuda index (steatosis r = -0.45, P < 0.001;
grade r = -0.54, P < 0.001; stage r = -0.37, P < 0.01), but not with hepatic insulin resis-
tance index. Multiple regression analyses adjusted for age, sex, body mass index and each
histological score showed that the degree of hepatic steatosis (coefficient = -0.22,
P < 0.05) and grade (coefficient = -0.40, P < 0.01) were associated with Matsuda index,
whereas the association between stage and Matsuda index (coefficient = -0.07,
P = 0.593) was no longer significant. A similar trend was observed for the association
between steatosis and metabolic clearance rate (coefficient = -0.62, P = 0.059).
Conclusions: Liver steatosis is associated with insulin resistance in skeletal muscle
rather than in the liver in patients with non-alcoholic fatty liver disease, suggesting a cen-
tral role of fatty liver in the development of peripheral insulin resistance and the existence
of a network between the liver and skeletal muscle.
INTRODUCTION
Insulin resistance is a central pathology, and is associated with
various metabolic abnormalities, including obesity, type 2 diabe-
tes, dyslipidemia and non-alcoholic fatty liver disease (NAFLD),
all of which are important risk factors for cardiovascular dis-
eases1,2. Whole-body insulin resistance is a composite of hepatic
and peripheral insulin resistance, and is best measured by the
euglycemic hyperinsulinemic clamp technique3. We previously
showed that liver steatosis, but not ﬁbrosis, is associated with
whole-body insulin resistance, independent of body mass index
(BMI), in patients with NAFLD4. However, it remains unclear
how liver histological features are associated with organ-speciﬁc
insulin resistance. When combined with radiolabeled glucose,
the euglycemic hyperinsulinemic clamp technique allows one to
quantify the individual contribution of organ-speciﬁc (hepatic
and skeletal muscle) insulin resistance to the defect in whole-
body insulin-mediated glucose disposal5. However, because this
technique is time-consuming and technically difﬁcult to carry
out, it cannot be applied in daily clinical practice or inReceived 5 April 2014; revised 3 July 2014; accepted 21 July 2014
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large-scale epidemiological studies. In recent years, surrogate
measures of insulin resistance from measurements of glucose
and insulin concentrations during the 75-g oral glucose toler-
ance test (OGTT) have been developed6–10. Furthermore, some
of these indices can selectively quantify organ-speciﬁc (hepatic
and muscle) insulin resistance7,10.
The aim of the present study was to examine the association
between liver histological features (steatosis, inﬂammation,
ﬁbrosis) and organ-speciﬁc (hepatic and skeletal muscle) insulin
resistance indices calculated from OGTT data in patients with
NAFLD.
MATERIALS AND METHODS
Participants and Study Design
We studied 72 patients clinically diagnosed with NAFLD, who
were recruited consecutively between 1999 and 2009 at Kanaza-
wa University Hospital, Kanazawa, Japan. They were in good
general health without evidence of any acute or chronic diseases
(other than NAFLD, type 2 diabetes, hypertension or dyslipide-
mia) as determined by history, physical examination, routine
blood chemistry, urinalysis and electrocardiography. In almost
all patients, the liver injury was identiﬁed during the treatment
of other metabolic disorders, such as diabetes mellitus and
obesity. In each patient, all other liver diseases were excluded,
including viral hepatitis B and C, primary biliary cirrhosis,
autoimmune hepatitis, sclerosing cholangitis, hemochromatosis,
Wilson’s disease, drug-induced liver injury and biliary obstruc-
tion. All patients reported drinking <20 g/day of ethanol. Of
the 72 patients, 48 (66%) had type 2 diabetes according to the
American Diabetes Association criteria11. Among these patients,
25 were treated with diet alone; the remainder were treated
with an a-glucosidase inhibitor (n = 3), a rapid-acting insulin
secretion agent (nateglinide, n = 3), or a pre-meal rapid-acting
insulin analog (n = 17). None of the patients were on medica-
tion (e.g. long-acting insulin, sulfonylureas, thiazolidinediones,
metformin, vitamin E or ursodeoxycholic acid) that could
inﬂuence fasting insulin/glucose levels or induce histological
changes in the liver. The patients gave their written informed
consent for this study, which was approved by the medical
ethics committee of Kanazawa University.
Evaluation of Insulin Sensitivity
After an overnight fast (10–12 h), an OGTT was carried out at
08.30 hours. Blood samples were obtained 0, 30, 60, 90 and
120 min after the glucose load for the measurement of plasma
glucose and insulin concentrations. The patients did not receive
any medication on the morning of the examination. Insulin
resistance indices were calculated from OGTT data as proposed
by Matsuda and DeFronzo7,10. The Matsuda index, an index of
whole-body (mainly skeletal muscle) insulin sensitivity, was
calculated using the following formula: Matsuda index =
10,000 / √ (fasting plasma glucose 9 fasting insulin [FPI]) 9
(mean glucose 9 mean insulin during OGTT)]. The hepatic
insulin resistance index was deﬁned as the product of the total
areas under the curve (AUC) for glucose and insulin during
the ﬁrst 30 min of the OGTT, and was calculated using the fol-
lowing formula: hepatic insulin resistance = (AUC[glucose]0–
30) 9 (AUC[insulin]0–30).
Insulin sensitivity was also evaluated using the euglycemic
hyperinsulinemic clamp method in 16 patients (seven with
diabetes and nine without diabetes). The patients did not receive
any medication on the morning of the examination. At approxi-
mately 09.00 hours, after an overnight fast of at least 10 h, an
intravenous catheter was placed in an antecubital vein of each
patient for infusion, and a second catheter was placed in the
contralateral hand for blood sampling. The euglycemic hyperins-
ulinemic clamp technique was carried out using an artiﬁcial
pancreas (model STG-22; Nikkiso, Tokyo, Japan), as described
previously. A solution of 0.8 U/mL insulin (Humulin R; Eli Lilly,
Indianapolis, IN, USA) in normal saline was allowed to remain
in the intravenous lines for at least 15 min, and the lines were
then ﬂushed before starting the insulin infusion. Insulin was
infused at a rate of 3.0 mU/kg/min, resulting in a steady-state
insulin concentration of 317.7 – 13.3 lU/mL (mean – standard
error of the mean), a level that might be sufﬁcient to suppress
hepatic glucose production (HGP). Blood glucose levels were
continuously determined during the clamp study, and main-
tained with variable-rate infusion of 20% glucose at a concentra-
tion of 100 mg/dL (or 90 mg/dL for baseline values under
90 mg/dL). The steady-state period was maintained for 30 min
or longer, during which the coefﬁcients of variation for blood
glucose and the glucose infusion rate were both <5%. The glu-
cose level reached during the clamp study was 95 – 4 mg/dL.
Because steady-state plasma glucose level affects the glucose
infusion rate (GIR) level, insulin sensitivity was expressed as the
glucose metabolic clearance rate (MCR), which was calculated
by adjusting GIR by steady-state plasma glucose. The mean
MCR in healthy subjects (n = 9; age 26.6 – 2.9 years; BMI
22.3 – 2.1 kg/m2) was 13.5 – 3.4 mg/kg/min.
Pathology
Ultrasound-guided liver biopsy specimens were obtained from
all 72 patients. Each specimen was stained with hematoxylin–
eosin and silver reticulin stains, and was examined histologically
by a pathologist who was blinded to the patient’s clinical condi-
tion and biochemical data. The biopsied tissues were scored for
steatosis (0, none; 1, <33%; 2, 33–66%; 3, >66%), grade and
stage, according to the standard criteria for grading and staging
of non-alcoholic steatohepatitis (NASH) proposed by Brunt
et al.12,13 in their studies.
Statistical Analyses
All analyses were carried out using the SPSS software version
11.0 (SPSS Inc., Chicago, IL, USA). All values are expressed as
the means – standard error of the mean, unless stated other-
wise. The relationship between individual variables was assessed
by Pearson’s correlation for parametric variables and by Spear-
man’s correlation for non- parametric variables. Multiple linear
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regression analysis was used to calculate age-, sex-, and BMI-
adjusted coefﬁcients for histological score and insulin resistance.
The t-statistic was used to compare the strength of the relation-
ship. Statistical signiﬁcance was deﬁned as P < 0.05.
RESULTS
Liver Histological Features and Clinical Characteristics in
Patients with NAFLD
The characteristics of the study participants and the number of
patients with each histological score are shown in Table 1.
Hepatic steatosis score was correlated with grade score
(r = 0.372, P = 0.001), but not with stage score (r = 0.224,
P = 0.059). Grade score and stage score were strongly corre-
lated with each other (r = 0.607, P < 0.001), suggesting that
inﬂammation causes ﬁbrosis in NAFLD.
Liver Histological Features and Organ-Speciﬁc (Hepatic and
Muscle) Insulin Resistance
We evaluated the associations between indices of insulin resis-
tance and histological scores of the liver. In a univariate analy-
sis, the degree of hepatic steatosis, and grade and stage of
NASH were signiﬁcantly correlated with Matsuda index
(mainly skeletal muscle insulin resistance; steatosis r = -0.45,
P < 0.001; grade r = -0.54, P < 0.001; stage r = -0.37,
P < 0.01), but were not correlated with hepatic insulin resis-
tance index (Table 2). The degree of hepatic steatosis was
signiﬁcantly correlated with MCR (r = -0.728, P = 0.001).
Multiple linear regression models were computed to assess
the relative age-, sex- and BMI-adjusted inﬂuence of each histo-
logical score on insulin resistance (Table 3). Steatosis (coefﬁ-
cient = -0.36, P < 0.01), grade (coefﬁcient = -0.51, P < 0.001)
and stage of NASH (coefﬁcient = -0.37, P < 0.01) were associ-
ated with Matsuda index, but not with hepatic insulin resis-
tance index. When these three histological scores were adjusted
for each other in a model that included all three simulta-
neously, the degree of hepatic steatosis (coefﬁcient = -0.22,
P < 0.05) and grade of NASH (coefﬁcient = -0.40, P < 0.01)
were associated with the Matsuda index. A similar independent
trend was observed between steatosis of the liver and MCR
(coefﬁcient = -0.62, P = 0.059).
DISCUSSION
In the present study, we investigated the associations between
liver histological features and indices of hepatic and skeletal
muscle insulin resistance in patients with NAFLD. We found
that liver steatosis was more strongly associated with skeletal
muscle insulin resistance than with hepatic insulin resistance.
The present results are consistent with a previous report in
which organ-speciﬁc (hepatic and skeletal muscle) insulin resis-
tance was assessed using the glucose clamp technique14. A
novel aspect of the present study was our evaluation of insulin
resistance using 75-g OGTT-derived indices, which are more
simple and practical in daily clinical practice than the glucose
clamp. Our ﬁndings suggest that hepatic steatosis per se is a
central surrogate pathology indicative of skeletal muscle insulin
resistance in patients with NAFLD. In addition, there could be
a network between the liver and skeletal muscle to maintain
whole-body energy homeostasis.
We evaluated insulin sensitivity using three indices: Matsuda
index, hepatic insulin resistance index and MCR. Various indi-
ces derived from 75-g OGTT data have been proposed as indi-
ces of skeletal muscle insulin sensitivity and hepatic insulin
resistance6–10. Above all, Matsuda index is strongly correlated
Table 1 | Clinical characteristics of the study participants
n 72
Age (years) 46.2 – 1.8
Sex (male/female) 39/33
BMI (kg/m2) 29.9 – 1.2
Fasting plasma glucose (mg/dL) 111 – 2
2 h glucose (mg/dL) 208 – 9
Basal insulin (lU/mL) 14.0 – 1.2
Insulinogenic index [(lU/mL)/(mg/dL)] 0.77 – 0.10
HOMA-IR 3.8 – 0.3
Matsuda index 2.8 – 0.2
Hepatic insulin resistance index 9 106 5.9 – 0.5
HbA1c (%) 6.8 – 0.2
Total cholesterol (mg/dL) 200 – 4
Triglycerides (mg/mL) 140 – 9
HDL cholesterol (mg/mL) 46 – 1
Aspartate aminotransferase (IU/L) 44 – 3






Angiotensin receptor blocker (+/-) 13/59
Insulin (+/-) 17/55
BMI, body mass index; HbA1c, hemoglobin A1c; HDL cholesterol, high-
density lipoprotein cholesterol; HOMA-IR, homeostasis model assess-
ment of insulin resistance. Data are presented as mean – standard error
of the mean or absolute numbers.
Table 2 | Univariate correlation between histological scores and insulin
resistance




r P r P r P
Steatosis -0.452 <0.001* 0.195 0.101 -0.728 0.001*
Grade -0.544 <0.001* 0.215 0.069 -0.149 0.581
Stage -0.369 0.001* 0.078 0.515 0.017 0.949
MCR, metabolic clearance rate. *A P-value <0.05 is considered statisti-
cally significant. †A euglycemic hyperinsulinemic clamp was carried out
in 16 patients.
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with insulin-stimulated total glucose disposal during the eugly-
cemic clamp, the gold standard of skeletal muscle insulin sensi-
tivity, and the correlation coefﬁcient is greater than for other
OGTT-derived indices of insulin sensitivity7,10. In contrast,
there has been no established gold standard marker of hepatic
insulin sensitivity. Considering evaluation of skeletal muscle
and hepatic insulin sensitivity in equal condition, the OGTT-
derived hepatic insulin sensitivity index should be based on
HGP suppression in hyperinsulinemic state. However, the Def-
ronzo group deﬁnes the product of fasting plasma insu-
lin 9 basal endogenous glucose production as a hepatic insulin
resistance index, and also observed that the hepatic insulin
resistance index (glucose0–30[AUC] insulin0–30[AUC])
strongly correlated with it10. Unfortunately, the conventional
index that correlates with HGP suppression under hyperinsuli-
nemic state still remains to be deﬁned. Therefore, we used the
Matsuda index and the hepatic insulin resistance index as indi-
ces of skeletal muscle insulin sensitivity and hepatic insulin
resistance, respectively. MCR represents the difference between
insulin-stimulated glucose disposal and HGP, and therefore
reﬂects insulin resistance in both skeletal muscle and the liver
to varying degrees depending on the insulin infusion rate in
the clamp study15. In the present clamp study, insulin was
infused at a rate of 3.0 mU/kg/min, resulting in a steady-state
insulin concentration of 317.7 – 13.3 lU/mL. Such supraphysi-
ological hyperinsulinemic condition might occupy the insulin
receptors and therefore could reﬂect postreceptor defects in
insulin signaling. In addition, that level might be sufﬁcient to
suppress HGP, and MCR mainly reﬂects skeletal muscle insulin
resistance under this condition (insulin infusion at rate:
3.0 mU/kg/min). However, because suppression of HGP is
impaired in type 2 diabetes, we cannot rule out the possibility
that MCR might reﬂect insulin resistance not only in skeletal
muscle, but also to some extent in the liver15. This might
explain the relatively weak association between steatosis score
and MCR in the present study.
We recently reported the similar association between liver fat
and organ-speciﬁc insulin resistance assessed by a euglycemic
hyperinsulinemic clamp with tracer infusion ([6,6-2H2]glucose)
16.
Unlike the present study, we observed the signiﬁcant correlation
between hepatic steatosis and HGP 9 FPI16. However, also in
that study, hepatic steatosis was more strongly correlated with
the skeletal muscle insulin resistance. These accumulating data,
together with the present ﬁndings, will clarify the signiﬁcance of
hepatic steatosis in energy homeostasis. Also, it should be
determined in future which index reﬂects best for authentic
hepatic insulin resistance among the proposed indices for hepatic
insulin resistance (the OGTT-derived hepatic insulin resistance
index, HGP 9 FPI, and %HGP).
In the present study, we were unable to ﬁnd any association
between liver histological score and insulin resistance in the
liver, although that score was associated with insulin resistance
in the distant skeletal muscle. Although the detailed mecha-
nisms still remain unclear, possible interorgan network, as
described later, might regulate the change in insulin resistance
resulting from pathogenesis of NAFLD greater in skeletal mus-
cle than in the liver. Whether hepatic steatosis is a consequence
or cause of skeletal muscle insulin resistance remains unclear.
One hypothesis is that skeletal muscle insulin resistance causes
obesity and subsequent hepatic steatosis, as shown experimen-
tally in mice with muscle-selective insulin resistance17. Indeed,
Flannery et al.18 reported that skeletal muscle insulin resistance
promotes increased hepatic de novo lipogenesis and hepatic
steatosis in the elderly. The second hypothesis is that a skeletal
muscle-derived hormone (myokine) could be overproduced in
patients with skeletal muscle insulin resistance, and might
induce liver steatosis19. Conversely, the third hypothesis is that
a liver-derived hormone (hepatokine)20 is overproduced in
patients with NAFLD, and mgiht affect the insulin sensitivity of
distant organs. We previously isolated the hepatokine, seleno-
protein P, which is overproduced in overnutrition, and causes
insulin resistance in both the liver and skeletal muscle21. Assay-
ing the levels of myokines and hepatokines will help us to
understand their contribution to the pathology of NAFLD. In
addition, complex mechanisms might underlie the causal role
of hepatic steatosis in the development of hepatic insulin resis-
tance. Recent studies suggest that triglyceride itself is not a toxic
lipid22. Rather, the accumulation of triglycerides might be a
Table 3 | Age-, sex- and body mass index-adjusted association between insulin resistance and histological scores of the liver
Matsuda index Hepatic insulin resistance index MCR†
Coefficient t-statistic P Coefficient t-statistic P Coefficient t-statistic P
Steatosis -0.36 -3.08 0.003* -0.60 -0.50 0.617 -0.62 -2.39 0.036*
Grade -0.51 -5.18 <0.001* 0.20 1.91 0.061 -0.08 -0.31 0.761
Stage -0.37 -3.47 0.001* 0.45 0.41 0.685 -0.08 -0.27 0.790
Steatosis‡ -0.22 -2.02 0.047* -1.44 -1.19 0.237 -0.62 -2.16 0.059
Grade† -0.40 -3.00 0.004* 0.36 2.43 0.018* -0.02 -0.04 0.969
Stage‡ -0.07 -0.54 0.593 -0.17 -1.21 0.229 -0.05 -0.12 0.909
MCR, metabolic clearance rate. All models were adjusted for age, sex and body mass index (BMI) by multiple linear regression. *A P-value <0.05 is
considered statistically significant. †A euglycemic hyperinsulinemic clamp was carried out in 16 patients. ‡Three histological scores are included in
the model.
ª 2014 The Authors. Journal of Diabetes Investigation published by AASD and Wiley Publishing Asia Pty Ltd J Diabetes Invest Vol. 6 No. 2 March 2015 161
O R I G I N A L A R T I C L E
http://onlinelibrary.wiley.com/journal/jdi Insulin resistance in fatty liver
protective mechanism to prevent toxic effects of free fatty acids.
Hepatic steatosis can occur independently of insulin resis-
tance20. In this regard, the quality of, rather than quantity of,
the accumulating lipid could determine hepatic insulin signal-
ing, and searching for toxic lipids that cause hepatic insulin
resistance should be required for understanding the pathophysi-
ology of fat-induced insulin resistance. We previously identiﬁed
cholesterol23 and palmitate24 as toxic lipids that cause mito-
chondria-derived oxidative stress and hepatic insulin resistance.
These might be the reasons why hepatic steatosis correlates
with insulin resistance in the skeletal muscle rather than in the
liver in the present study.
The present study had several limitations. First, most of the
participants were diabetes patients. Therefore, insulin resistance
might be greater in these study subjects than in the general
population, which could have inﬂuenced the results. In future
studies, direct evaluation of organ-speciﬁc insulin resistance by
using the euglycemic hyperinsulinemic clamp with tracer will
better validate the present conclusion in NAFLD patients with
and without diabetes. Second, the number of study participants
with severe ﬁbrosis (stage 3 or 4) was relatively small, and the
study participants might therefore not have fully shown patho-
physiological conditions of ﬁbrosis. Third, we could not evalu-
ate insulin sensitivity in equal condition (hepatic insulin
resistance index and Matsuda index are based on index in a
fasting and hyperinsulinemic state, respectively). Fourth, the
present study was an observational design, and so we could not
evaluate causal associations. A large-scale longitudinal study is
required to clarify whether hepatic steatosis is a consequence or
cause of skeletal muscle insulin resistance.
In summary, the present study showed that liver steatosis is
associated with insulin resistance in skeletal muscle rather than
in the liver, suggesting a central role of fatty liver in the devel-
opment of insulin resistance, and that a network between the
liver and skeletal muscle maintains whole-body energy homeo-
stasis.
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